De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

Auteurs : Curigliano G, Burstein HJ, P Winer E, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, Thürlimann B, André F, Baselga J, Bergh J, Bonnefoi H, Y Brucker S, Cardoso F, Carey L, Ciruelos E, Cuzick J, Denkert C, Di Leo A, Ejlertsen B, Francis P, Galimberti V, Garber J, Gulluoglu B, Goodwin P, Harbeck N, Hayes DF, Huang CS, Huober J, Hussein K, Jassem J, Jiang Z, Karlsson P, Morrow M, Orecchia R, Osborne KC, Pagani O, Partridge AH, Pritchard K, Ro J, Rutgers EJT, Sedlmayer F, Semiglazov V, Shao Z, Smith I, Toi M, Tutt A, Viale G, Watanabe T, Whelan TJ, Xu B
Année : 2017
Journal : Ann Oncol
Volume : 28
Pages : 1700-1712

ESMO-Magnitude of Clinical Benefit Scale version 1.1.

Auteurs : Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart-Gebhart M, de Vries EGE
Année : 2017
Journal : Ann Oncol
Volume : 28
Pages : 2340-2366

HER2-positive breast cancer is lost in translation: time for patient-centered research.

Auteurs : Gingras I, Gebhart G, de Azambuja E, Piccart-Gebhart M
Année : 2017
Journal : Nat Rev Clin Oncol
Volume : 14(11)
Pages : 669-681

Targeting immune checkpoints in breast cancer: an update of early results.

Auteurs : Solinas C, Gombos A, Latifyan S, Piccart-Gebhart M, Kok M, Buisseret L
Année : 2017
Journal : ESMO Open
Volume : 2
Pages : e000255

Reply to: Re-Aligning the ASCO and ESMO Clinical Benefit Frameworks or Modern Cancer Therapies.

Auteurs : Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, Tabernero J, Zielinski C, Piccart-Gebhart M, de Vries EGE
Année : 2017
Journal : Ann Oncol
Volume : 29(3):
Pages : 774-775

Immune Checkpoint Molecules on Tumor-Infiltrating Lymphocytes and Their Association with Tertiary Lymphoid Structures in Human Breast Cancer.

Auteurs : Solinas C, Garaud S, De Silva P, Boisson A, Van den Eynden G, de Wind A, Risso P, Rodrigues Vitória J, Richard F, Migliori E, Noël G, Duvillier H, Craciun L, Veys I, Awada A, Detours V, Larsimont D, Piccart-Gebhart M, Willard-Gallo K
Année : 2017
Journal : Front Immunol
Volume : 8
Pages : 1412

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Auteurs : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Année : 2017
Journal : Nat Commun
Volume : 8
Pages : 15759

Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer.

Auteurs : Buisseret L, Desmedt C, Garaud S, Fornili M, Wang X, Van den Eyden G, de Wind A, Duquenne S, Boisson A, Naveaux C, Rothé F, Rorive S, Decaestecker C, Larsimont D, Piccart-Gebhart M, Biganzoli E, Sotiriou C, Willard-Gallo K
Année : 2017
Journal : Mod Pathol
Volume : 30(9)
Pages : 1204-1212

Characterisation of multifocal breast cancer using the 70-gene signature in clinical low-risk patients enrolled in the EORTC 10041/BIG 03-04 MINDACT trial.

Auteurs : Aalders KC, Kuijer A, Straver ME, Slaets L, Litiere S, Viale G, Vant Veer LJ, Glas AM, Delorenzi M, van Dalen T, Tryfonidis K, Piccart-Gebhart M, Cardoso F, Rutgers EJ
Année : 2017
Journal : Eur J Cancer
Volume : 79
Pages : 98-105

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Auteurs : Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart-Gebhart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C
Année : 2017
Journal : Nat Commun
Volume : 8
Pages : 14944

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

Auteurs : Sonnenblick A, Agbor-Tarh D, Bradbury I, Di Cosimo S, Azim HA Jr, Fumagalli D, Sarp S, Wolff AC, Andersson M, Kroep J, Cufer T, Simon SD, Salman P, Toi M, Harris L, Gralow J, Keane M, Moreno-Aspitia A, Piccart-Gebhart M, de Azambuja E
Année : 2017
Journal : J Clin Oncol
Volume : 35
Pages : 1421-1429

Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.

Auteurs : Gingras I, Holmes E, de Azambuja E, Nguyen DH, Izquierdo M, Anne Zujewski J, Inbar M, Naume B, Tomasello G, Gralow JR, Wolff AC, Harris L, Gnant M, Moreno-Aspitia A, Piccart-Gebhart M, Azim HA Jr
Année : 2017
Journal : J Natl Cancer Inst
Volume : 109

HER2-overexpressing breast cancers amplify FGFR signaling upon acquisition of resistance to dual therapeutic blockade of HER2.

Auteurs : Hanker AB, Garrett JG, Estrada MV, Moore PD, Ericsson PG, Koch JP, Langley E, Singh S, Kim PS, Frampton GM, Sanford EM, Owns P, Becker J, Groseclose MR, Castellino S, Joensuu H, Huober J, Brase JC, Samira M, Brohée S, Venet D, Brown D, Baselga J, Piccart-Gebhart M, Sotiriou C, Arteaga CL
Année : 2017
Journal : Clin Cancer Res
Volume : 23(15)
Pages : 4323-4334

Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.

Auteurs : Ades F, Senterre C, Zardavas D, de Azambuja E, Popescu R, Piccart-Gebhart M
Année : 2017
Journal : PLoS One
Volume : 12(3)
Pages : e0172351

Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Stu

Auteurs : Zardavas D, Suter TM, van Veldhuisen DJ, Steinseifer J, Noe J, Lauer S, Al-Sakaff N, Piccart-Gebhart M, de Azambuja E
Année : 2017
Journal : J Clin Oncol
Volume : 35(8)
Pages : 878-884

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Auteurs : Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L
Année : 2017
Journal : Ann Oncol
Volume : 28
Pages : 128-135

Corrigendum to 3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)" [Breast 31 (February 2017) 244-259]."

Auteurs : Cardoso F, Costa A, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Bhattacharyya G, Biganzoli L, Cardoso MJ, Carey L, Corneliussen-James D, Curigliano G, Dieras V, El Saghir N, Eniu A, Fallowfield L, Fenech D, Francis P, Gelmon K, Gennari A, Harbeck N, Hudis C, Kaufman B, Krop I, Mayer M, Meijer H, Mertz S, Ohno S, Pagani O, Papadopoulos E, Peccatori F, Penault-Llorca F, Piccart-Gebhart M, Pierga JY, Rugo H, Shockney L, Sledge G, Swain S, Thomssen C, Tutt A, Vorobiof D, Xu B, Norton L, Winer E
Année : 2017
Journal : Breast
Volume : 32
Pages : 269-270

11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial.

Auteurs : Cameron D, Piccart-Gebhart M, Gelber Rd, Procter M, Goldhirsch A, de Azambuja E, Castro G Jr, Untch M, Smith I, Gianni L, Baselga J, Al-Sakaff N, Lauer S, Mcfadden E, Leyland-Jones B, Bell R, Dowsett M, Jackisch C
Année : 2017
Journal : Lancet
Volume : 389(10075)
Pages : 1195-1205

The prognostic role of androgen receptor in patients with early stage breast cancer: A meta-analysis of clinical and gene expression data.

Auteurs : Bozovic-Spasojevic I, Zardavas D, Brohée S, Ameye L, Fumagalli D, Ades F, de Azambuja E, Bareche Y, Piccart-Gebhart M, Paesmans M, Sotiriou C
Année : 2017
Journal : Clin Cancer Res
Volume : 23(11)
Pages : 2702-2712

Reply to the letter to the editor 'Addressing the quality of the ESMO-MCBS' by Del Paggio.

Auteurs : Cherny NI, Dafni U, Bogaerts J, Pentheroudakis G, Tabernero J, Zielinski C, Piccart-Gebhart M, de Vries EGE
Année : 2017
Journal : Ann Oncol
Volume : 28
Pages : 2031-2032